Announcements Trials
Browse Landscape

Phase

Phase NA 3Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Radiation Injuries 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Thymoma 1Thymic epithelial tumor 1Squamous Cell Carcinoma of Head and Neck 1Nasopharyngeal Carcinoma 1Melanoma 1Carcinoma, Transitional Cell 1Carcinoma, Hepatocellular 1

Interventions

Bevacizumab 69Sorafenib 66lenvatinib 59durvalumab 38sintilimab 33Nivolumab 32tislelizumab 28atezolizumab 28pembrolizumab 27Oxaliplatin 26tremelimumab 23apatinib 22Fluorouracil 22Radiosurgery 20regorafenib 19camrelizumab 18Doxorubicin 18cabozantinib 16Leucovorin 16Capecitabine 16Radiotherapy 14Folfox protocol 14donafenib 13Gemcitabine 13Cisplatin 12toripalimab 11Erlotinib Hydrochloride 10spartalizumab 8anlotinib 8Neoadjuvant Therapy 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Hepatocellular × Heavy Ion Radiotherapy × Clear all
NCT02946138 2019-09-09

Phase II Trial of Carbon-ion Radiotherapy Combined With GM-CSF for the Treatment of Hepatocellular Carcinoma

Shanghai Proton and Heavy Ion Center

Phase 2 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡